Putting GlaxoSmithKline to the test over paroxetine
dc.contributor.author | Doshi, Peter | |
dc.date.accessioned | 2017-05-25T01:19:05Z | |
dc.date.available | 2017-05-25T01:19:05Z | |
dc.date.issued | 2013-11-12 | |
dc.identifier.citation | Doshi, P. (2013). Putting GlaxoSmithKline to the test over paroxetine. BMJ, 347. DOI: 10.1136/bmj.f6754 | |
dc.identifier.uri | http://hdl.handle.net/10713/6614 | |
dc.description | Author discusses paroxetine, an antidepressant manufactured by GlaxoSmithKline, its use in adolescents, the controversy over Study 329, and the company's continued reticence to share all of its clinical trial data. | |
dc.description.uri | http://bmj.com/cgi/content/full/bmj.f6754?ijkey=daKgBqzhyNXwNUW&keytype=ref | |
dc.language.iso | en_US | en_US |
dc.publisher | BMJ Publishing Group | en_US |
dc.subject | research transparency | en_US |
dc.subject | Restoring Invisible and Abandoned Trials | en_US |
dc.subject | RIAT | en_US |
dc.subject | Study 329 | en_US |
dc.subject.lcsh | GlaxoSmithKline | en_US |
dc.subject.mesh | Access to Information | en_US |
dc.subject.mesh | Adolescent | en_US |
dc.subject.mesh | Clinical Trials as Topic | en_US |
dc.subject.mesh | Depression | en_US |
dc.subject.mesh | Paroxetine | en_US |
dc.title | Putting GlaxoSmithKline to the test over paroxetine | en_US |
dc.type | Article | en_US |
dc.identifier.doi | 10.1136/bmj.f6754 | |
dc.identifier.pmid | 24222673 | |
dc.identifier.ispublished | No | en_US |
dc.description.uriname | Click here for the free full-text article on publisher’s website | en_US |
refterms.dateFOA | 2019-02-19T18:16:22Z |